

In re Pharmaceutical Industry Average Wholesale Price Litigation , MDL - 1456

Track 2 Settlement

Analysis of 20 of the 22 Admitted Single-Source Branded Drugs Currently in Group B

EXHIBIT "B"

Drug	Manufacturer	Overcharge % (Using Hartman Calculated Total Overcharge % for Each Company)*	NOTES	Claims (Coggeshall Declaration)	Pro Rata Payment After Latest Rebalancing (14.087%)	Damage Based Payment (Using Hartman Calculated Total Overcharge % for Each Company)	Double Damages (Using Hartman Calculated Total Overcharge % for Each Company)	Difference Between Payment of Double Damages and Current Pro Rata Payment
1 Accuneb	Dey	78.10%		\$965,221.12	135,970.70	\$753,837.69	\$1,507,675.39	\$1,371,704.69
2 Aromasin	Pfizer/Pharmacia	60.10%		\$159,357.15	22,448.64	\$95,773.65	\$191,547.29	\$169,098.65
3 Azmacort	Abbott	89.20%		\$603.86	85.07	\$538.64	\$1,077.29	\$992.22
4 Calcijex	Abbott	89.20%		\$2,116,604.29	298,166.05	\$1,888,011.03	\$3,776,022.05	\$3,477,856.01
5 Calcimar	Aventis	37.50%		\$12,448.94	1,753.68	\$4,668.35	\$9,336.71	\$7,583.02
6 Campitosar	Pfizer/Pharmacia	60.10%		\$3,562,867.33	501,901.12	\$2,141,283.27	\$4,282,566.53	\$3,780,665.41
7 Cefizox	Fujisawa	12.00%		\$931.34	131.20	\$111.76	\$223.52	\$92.32
8 Cipro	Bayer	32.60%		\$1,321.33	186.14	\$430.75	\$861.51	\$675.37
9 Depo provera	Pfizer/Pharmacia	60.10%		\$2,673.62	376.63	\$1,606.85	\$3,213.69	\$2,837.06
10 Ellence	Pfizer/Pharmacia	60.10%		\$575,652.79	81,092.21	\$345,967.33	\$691,934.65	\$610,842.45
11 Enbrel	Pfizer/Pharmacia	60.10%		\$9,049.12	1,274.75	\$5,438.52	\$10,877.04	\$9,602.29
12 Idamycin	Pfizer/Pharmacia	60.10%		\$13,791.27	1,942.78	\$8,288.55	\$16,577.11	\$14,634.33
13 Leukine	Bayer	32.60%		\$634,025.35	89,315.15	\$206,692.26	\$413,384.53	\$324,069.38
14 Lovenox	Aventis	37.50%		\$44,736.05	6,301.97	\$16,776.02	\$33,552.04	\$27,250.07
15 Mithracin	Bayer	32.60%		\$144.91	20.41	\$47.24	\$94.48	\$74.07
16 Novantrone	Immunex	3.00%	Dr. Hartman provided actual Overcharge Ratio for Novantrone	\$546,473.65	76,981.74	\$16,394.21	\$32,788.42	(\$44,193.32)
17 Prograf	Fujisawa	12.00%		\$4,628,818.41	652,061.65	\$555,458.21	\$1,110,916.42	\$458,854.77
18 Taxotere	Aventis	37.75%		\$6,377,215.77	898,358.39	\$2,407,398.95	\$4,814,797.91	\$3,916,439.52
19 Thioplex	Immunex	33.70%		\$23,512.54	3,312.21	\$7,923.73	\$15,847.45	\$12,535.24
20 Zemplar	Abbott	89.20%		\$17,001,632.09	2,395,019.91	\$15,165,455.82	\$30,330,911.65	\$27,935,891.74
Subtotals:								
Additional Funds Needed to Pay Claimants Double Damages:								
\$42,077,505.28								

* Though Class Counsel acknowledge that these twenty (20) drugs (as well as Eligard and Trelstar) are single-source branded drugs, *see* Brief at 11, with the exception of Novantrone, they inexplicably did not ask Dr. Hartman to calculate an overcharge ratio for these drugs, or analyze them in any matter. Accordingly, for purposes of analyzing the damage-based approach to the payment of claims for these drugs, Certain Named Plaintiffs' counsel used the total overcharge ratio for the respective manufacturers for each of the above drugs.

The exception to that rule is with the Aventis drugs. Because Dr. Hartman did not provide a total Overcharge Ratio for all of the Aventis drugs and only provided said ratio for Anzemet Tablets (19.8%) and Anzemet Injectable (55.7%) individually, this chart uses the average of the two (37.5%) for Calcimar, Lovenox and Taxotere.